Skip to content
Search

Latest Stories

In Thorrun Govind, English Pharmacy Board gets youngest chair ever

Thorrun Govind was today (22 June) elected as chair of the English Pharmacy Board (EPB), becoming the youngest ever to hold the position since the Royal Pharmaceutical Society shed its regulatory function to become the new professional leadership body in 2010. She is 28 years old.

Govind also becomes the second female chair of colour, after Shilpa Gohil who was elected as EPB chair in 2012.


Giving her reaction to Pharmacy Business immediately after the announcement, a delighted Govind termed it as an honour to serve the membership body and the wider profession. “I’m going to be chairing an inclusive, communicative and strategic board that engages with stakeholders and puts pharmacy at the heart of everything we do,” she added.

She said she will look to connect better with the members and non-members and ensure their views are being listened too, and called on young pharmacists to take up leadership roles.

“I feel that it is important for younger members of the profession to know that age is not a barrier to leadership. We can all show leadership in our own individual way. I firmly believe that we are all ambassadors for the profession,” she said in a tweet.

Asked what her immediate priorities were, Thorrun -- who won the 'Pharmacy Business Young Pharmacist of the Year' award in 2018 -- said she would use her communications and media experience "to connect better with the members and non-members and to ensure that their views are being listened too."

Martin Astbury is elected as vice-chair of the board. Claire Anderson, Sibby Buckle, Tase Oputu and Alisdair Jones will be the EPB’s representatives to the RPS Assembly.

For the Welsh Pharmacy Board, Cheryl Way has been elected as Board chair, with Ruth Mitchell elected as both vice-chair and the representative to the Assembly. Seconded on to the board in the hospital pharmacy position is Geraldine McCaffrey.

Andrew Carruthers has been elected as the chair of the Scottish Pharmacy Board, and Kathleen Cowle will become both vice-chair and the representative to the Assembly.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less